Chen Zhu

Dr. Chen Zhu

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2023 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
ZGZiang Geng
Ziang Geng
SGShu Guan
Shu Guan
SWSiqi Wang
Siqi Wang
ZYZhongxue Yu
Zhongxue Yu
TLTiancong Liu
Tiancong Liu
CZChen Zhu
Chen Zhu
Aim: Mitochondria is one of the important organelles involved in cell energy metabolism and regulation and also play a key regulatory role in abnormal cell processes such as cell stress, cell damage, and cell canceration. Recent studies have shown that mitochondria can be transferred between cells in different ways and participate in the occurrence and development of many central nervous system diseases. We aim to review the mechanism of mitochondrial transfer in the progress of central nervous system diseases and the possibility of targeted therapy.Methods: The PubMed databank, the China National Knowledge Infrastructure databank, and Wanfang Data were searched to identify the experiments of intracellular mitochondrial transferrin central nervous system. The focus is on the donors, receptors, transfer pathways, and targeted drugs of mitochondrial transfer.Results: In the central nervous system, neurons, glial cells, immune cells, and tumor cells can transfer mitochondria to each other. Meanwhile, there are many types of mitochondrial transfer, including tunneling nanotubes, extracellular vesicles, receptor cell endocytosis, gap junction channels, and intercellular contact. A variety of stress signals, such as the release of damaged mitochondria, mitochondrial DNA, or other mitochondrial products and the elevation of reactive oxygen species, can trigger the transfer of mitochondria from donor cells to recipient cells. Concurrently, a variety of molecular pathways and related inhibitors can affect mitochondrial intercellular transfer.Conclusion: This study reviews the phenomenon of intercellular mitochondrial transfer in the central nervous system and summarizes the corresponding transfer pathways. Finally, we propose targeted pathways and treatment methods that may be used to regulate mitochondrial transfer for the treatment of related diseases.

19 June 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
XMXiao Ma
Xiao Ma
ZGZiang Geng
Ziang Geng
SWSiqi Wang
Siqi Wang
ZYZhongxue Yu
Zhongxue Yu
TLTiancong Liu
Tiancong Liu
CZChen Zhu
Chen Zhu
The difficulty and poor prognosis of malignant tumor have always been a difficult problem to be solved. The internal components of solid tumor are complex, including tumor cells, stromal cells and immune cells, which play an important role in tumor proliferation, migration, metastasis and drug resistance. Hence, targeting of only the tumor cells will not likely improve survival. Various studies have reported that tumor cells and endothelial cells have high plasticity, which is reflected in the fact that they can simulate each other's characteristics by endothelial-mesenchymal transition (EndMT) and vasculogenic mimicry (VM). In this paper, this mutual mimicry concept was integrated and reviewed for the first time, and their similarities and implications for tumor development are discussed. At the same time, possible therapeutic methods are proposed to provide new directions and ideas for clinical targeted therapy and immunotherapy of tumor.

8 December 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
XCXin Chen
Xin Chen
TLTianqi Liu
Tianqi Liu
JWJianqi Wu
Jianqi Wu
CZChen Zhu
Chen Zhu
GGGefei Guan
Gefei Guan
AWAn-hua Wu
An-hua Wu
Tumor protein 53 mutation ( TP53mut ) is one of the most important driver events facilitating tumorigenesis, which could induce a series of chain reactions to promote tumor malignant transformation. However, the malignancy progression patterns under TP53 mutation remain less known. Clarifying the molecular landscapes of TP53mu t tumors will help us understand the process of tumor development and aid precise treatment. Here, we distilled genetic and epigenetic features altered in TP53mut cancers for cluster-of-clusters analysis. Using integrated classification, we derived 5 different subtypes of TP53mut patients. These subtypes have distinct features in genomic alteration, clinical relevance, microenvironment dysregulation, and potential therapeutics. Among the 5 subtypes, COCA3 was identified as the subtype with worst prognosis, causing an immunosuppressive microenvironment and immunotherapeutic resistance. Further drug efficacy research highlighted olaparib as the most promising therapeutic agents for COCA3 tumors. Importantly, the therapeutic efficacy of olaparib in COCA3 and immunotherapy in non-COCA3 tumors was validated via in vivo experimentation. Our study explored the important molecular events and developed a subtype classification system with distinct targeted therapy strategies for different subtypes of TP53mut tumors. These multiomics classification systems provide a valuable resource that significantly expands the knowledge of TP53mut tumors and may eventually benefit in clinical practice.

21 February 2025 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
ZGZiang Geng
Ziang Geng
ZZZheyuan Zhang
Zheyuan Zhang
MWMiaohan Wang
Miaohan Wang
ZYZhongxue Yu
Zhongxue Yu
SWSiqi Wang
Siqi Wang
CZChen Zhu
Chen Zhu
Glioma is the most common primary malignant tumor of the central nervous system in adults, characterized by high mortality, low cure rate and high recurrence rate. Among gliomas, glioblastoma multiforme (GBM) is the most malignant subtype. Currently, the standard treatment for patients with GBM is maximum surgical excision combined with radiotherapy and chemotherapy. But only a small percentage of patients benefit from this standard treatment. The tumor microenvironment plays an important role in the occurrence and development of most tumors. It is primarily composed of tumor cells, peripheral blood vessels, extracellular matrix, signaling molecules, stromal cells, and immune cells. The role of stromal cells in GBM has emerged as the focus of current research. The interaction among tumor, stromal, and immune cells within the tumor microenvironment can influence tumor development. Traditional research and drug therapy in glioma mainly focus on the tumor cells themselves, but recent studies have found that targeting stromal cells in the tumor microenvironment can also modulate tumor progression in GBM. Here, we review the influence of stromal cells in the tumor microenvironment of GBM on tumor cells and its related mechanism, as well as related molecular targets and signaling pathways, providing new ideas for the treatment and prognosis of GBM.

26 March 2026 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
JLJun Lu
Jun Lu
SCSiwen Chu
Siwen Chu
SWShisong Wang
Shisong Wang
SWSiqi Wang
Siqi Wang
ZYZhongxue Yu
Zhongxue Yu
CZChen Zhu
Chen Zhu
The immunosuppressive and therapy-resistant nature of glioblastoma (GBM) is fundamentally driven by the profound spatiotemporal and metabolic heterogeneity of tumor-associated macrophages (TAMs). This review proposes a spatiotemporal-metabolic axis as an integrative framework to decipher the functional plasticity of TAMs and its therapeutic implications. Drawing on the latest single-cell and spatial multi-omics data, we first delineate the lineage competition landscape of TAMs. Within this landscape, brain-resident microglia, border-associated macrophages (BAMs), and peripherally recruited bone marrow-derived macrophages (BMDMs) engage in dynamic interplay during tumor evolution, culminating in a shifted ecosystem dominated by BMDMs at recurrence. These subsets are not randomly distributed but are spatially organized through niche-instructive signals—such as hypoxia, perivascular cues, and tumor-derived metabolites—leading to context-dependent enrichment: immunosuppressive TAMs accumulate in the tumor core, BAMs localize to perivascular zones and express pro-angiogenic factors, while hypoxic necrotic regions are populated by metabolically reprogrammed HMOX1 + TAMs. Metabolically, TAMs engage in symbiotic nutrient exchange with glioma cells via enhanced glycolysis, amino acid catabolism, and lipid accumulation, collectively reinforcing an immunosuppressive microenvironment. Building on this multidimensional understanding, we highlight emerging therapeutic strategies that move beyond broad depletion: metabolic-epigenetic interference (e.g., targeting lactate-driven histone lactylation), phagocytosis checkpoint blockade (e.g., CD47-SIRPα axis), and niche-precise targeting of hypoxic or perivascular TAM subsets. This review provides an integrative roadmap for developing next-generation immunotherapies that leverage the spatiotemporal and metabolic logic of TAMs to reprogram the GBM microenvironment.

31 October 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SWShisong Wang
Shisong Wang
JLJun Lu
Jun Lu
JLJingyou Li
Jingyou Li
ZYZihao Yan
Zihao Yan
ZYZhongxue Yu
Zhongxue Yu
JZJingyu Zou
Jingyu Zou
Gliomas, notably high-grade variants, dominate the spectrum of central nervous system (CNS) malignancies, characterized by aggressive behavior and diffuse invasion. Despite advances in tumor immunology, patient outcomes are stagnant. Amino acid metabolism is pivotal in glioma progression, driving the quest for metabolic targets. Bioinformatics allows deep dives into large-scale patient data from TCGA, CGGA, and GEO. Comparative studies on glioma amino acid metabolism have identified genes associated with tumor characteristics and patient survival. This yields an amino acid metabolism-based risk score model, which elucidates key biological processes and signaling pathways. Our holistic strategy clarifies amino acid metabolism’s role in glioma onset, paves the way for targeted therapies. Precise analysis and strategic targeting of metabolic pathways hold great promise for improving glioma treatment, offering hope to patients battling this relentless CNS malignancy.